Dr. Tardif’s research covers the molecular and genomic aspects of atherosclerosis and related diseases and also involves animal models, mechanistic and observational clinical studies as well as large international randomized clinical trials. Dr Tardif is or has been the international principal investigator or part of the study leadership of several large clinical trials in the field of atherosclerosis and other cardiovascular diseases. Dr Tardif and his team have created the Beaulieu-Saucier Pharmacogenomics Center at the Montreal Heart Institute and he has created the Center of Excellence in Personalized Medicine, the latter funded by the Network of Centers of Excellence of Canada and which is also supported by multiple pharmaceutical and biotechnological companies. He is one of the founding members of the Critical Markers of Disease organization, which focuses on the development and better use of biomarkers (www.cmod.org).